ScreenerHero

NEUP Neuphoria Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · neuphoriatx.com
3.420USD-0.87%Mkt Cap: 18.51M $P/E: —

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap18.51M USD
Enterprise Value-1.16M USD
Revenue (TTM)1.17M USD
Gross Profit1.17M USD
Net Income (TTM)-13.45M USD
Revenue/Share0.27 USD
Last Price3.420 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.40
PEG—
EV/EBITDA0.14
EV/Revenue-0.99
P/S15.90
P/B0.63
EPS (TTM)-3.06
EPS (Forward)-2.46
52W Range
3.1901% of range21.40
52W High21.40 USD
52W Low3.190 USD
Profitability
Gross Margin100.00%
Oper. Margin-15.66%
EBITDA Margin0.00%
Profit Margin-1145.66%
ROE-54.68%
ROA-46.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.35M USD
CapEx (TTM)—
FCF Margin-710.21%
FCF Yield-45.06%
Net Debt-19.83M USD
Net Debt/EBITDA2.38
Balance Sheet
Debt/Equity0.00
Current Ratio27.85
Quick Ratio27.33
Book Value/Sh5.47 USD
Cash/Share3.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateDec 24, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.41M
Float5.37M
Insiders5.02%
Institutions42.23%
Short Interest
Short Ratio0.5d
Short % Float0.46%
Short % Out.0.46%
Shares Short24.71K
Short (prev mo.)42.03K
Technical
SMA 503.778 (-9.5%)
SMA 2004.217 (-18.9%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)24.55K
Avg Vol (10d)9.96K
Technical Indicators
RSI (14)25.6
MACD-0.0942
MACD Signal-0.0716
MACD Hist.-0.0226
BB Upper3.881 USD
BB Middle3.637 USD
BB Lower3.393 USD
BB Width13.41%
ATR (14)0.0922 USD
Vol Ratio (20d)0.27x